Literature DB >> 6234240

Clinical and immunobiological effects of an orally administered bacterial extract.

G J Maestroni, G A Losa.   

Abstract

The effect of a bacterial extract orally administered to 20 children with recurrent infections of the upper respiratory tract, was investigated in a double-blind study. The composition of the peripheral blood mononuclear cells (T and B-lymphocytes, monocytes) and some of their biochemical properties (5'-nucleotidase, beta-N-acetyl-glucosaminidase and non-specific esterase) were unaffected. In contrast, the allogeneic mixed lymphocyte reaction was significantly increased in patients treated with the bacterial extract. In the treated group the number of infectious episodes decreased significantly and the clinical response correlated positively with the mixed lymphocyte reaction. These findings suggest that the bacterial extract has the capacity of restoring depressed immune functions by acting through the gut-associated lymphoid tissue.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6234240     DOI: 10.1016/0192-0561(84)90005-5

Source DB:  PubMed          Journal:  Int J Immunopharmacol        ISSN: 0192-0561


  13 in total

1.  Immunomodulation with bacterial extracts in respiratory diseases.

Authors:  A G Palma-Carlos; M L Palma-Carlos
Journal:  Lung       Date:  1990       Impact factor: 2.584

2.  Effects of a bacterial extract on local immunity of the lung in patients with chronic bronchitis.

Authors:  B Emmerich; H P Emslander; D Milatovic; M Hallek; K Pachmann
Journal:  Lung       Date:  1990       Impact factor: 2.584

Review 3.  Similarities and discrepancies between exacerbations of asthma and chronic obstructive pulmonary disease.

Authors:  L Fabbri; B Beghé; G Caramori; A Papi; M Saetta
Journal:  Thorax       Date:  1998-09       Impact factor: 9.139

Review 4.  Oral purified bacterial extracts in acute respiratory tract infections in childhood: a systematic quantitative review.

Authors:  Claudia Steurer-Stey; Leonie Lagler; Daniel A Straub; Johann Steurer; Lucas M Bachmann
Journal:  Eur J Pediatr       Date:  2006-11-18       Impact factor: 3.183

5.  OM85-BV induced the productions of IL-1β, IL-6, and TNF-α via TLR4- and TLR2-mediated ERK1/2/NF-κB pathway in RAW264.7 cells.

Authors:  Hong Luan; Qian Zhang; Le Wang; Chuanxiao Wang; Miao Zhang; Xiaoli Xu; Huan Zhou; Xing'ai Li; Qing Xu; Fan He; Jin Yuan; Yongman Lv
Journal:  J Interferon Cytokine Res       Date:  2014-03-07       Impact factor: 2.607

6.  Preventive effects of an immunostimulating product on recurrent infections of chronic bronchitis in the elderly.

Authors:  N Debbas; J P Derenne
Journal:  Lung       Date:  1990       Impact factor: 2.584

Review 7.  OM-85 BV, an immunostimulant in pediatric recurrent respiratory tract infections: a systematic review.

Authors:  Urs B Schaad
Journal:  World J Pediatr       Date:  2010-02-09       Impact factor: 2.764

8.  Prevention of recurrent rhinopharyngitis in at-risk children in France: a cost-effectiveness model for a nonspecific immunostimulating bacterial extract (OM-85 BV).

Authors:  Jean-Jacques Pessey; Françoise Mégas; Benoît Arnould; Florence Baron-Papillon
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

9.  Prevention of infection in immunosuppressive patients with autoimmune nephrosis by using an immunostimulating bacterial lysate Broncho-vaxom.

Authors:  Miao Zhang; Hong Luan; Qian Zhang; Le Wang; Yong-Man Lv; Fan He; Yan Chen; Hong-Bing Zeng; Ying Yao; Qin Liu
Journal:  Hum Vaccin Immunother       Date:  2012-08-24       Impact factor: 3.452

10.  Inhibition of spontaneous pulmonary metastases of Lewis lung carcinoma by oral treatment with Respivax and Broncho-Vaxom.

Authors:  K T Kassabov; J N Stoychkov
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.